• Skip to primary navigation
  • Skip to main content
  • Skip to footer
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

Hide Search
Shopping Cart
Show SearchSearch
866.626.6847
  • About
    • Our Work
    • Our Team
    • Our Partners
  • Exposures
    • Pregnancy and Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
  • Studies
    • Ongoing Studies
    • What’s Involved?
    • Join Now
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Meetings
    • FAQs
    • OTIS Membership
  • Media
    • Media Requests
    • Press Releases
    • eNews Sign Up
  • In Your Area
  • OTIS
    • About OTIS
    • OTIS Membership
    • Annual Meeting
    • Member Log-In
    • Donate
  • Contact
  • Show SearchSearch

Magnetic Resonance Imaging (MRI)

April 1, 2022

Selected References

  • American College of Obstetricians and Gynecologists (ACOG). 2017. Committee Opinion No. 723. Guidelines for diagnostic imaging during pregnancy and lactation. Obstet Gynecol, 130(4):933-934.
  • American College of Radiology. (2020).ACR Manual on MR Safety. [PDF file]. Retrieved from https://www.acr.org/-/media/ACR/Files/Radiology-Safety/MR-Safety/Manual-on-MR-Safety.pdf.
  • Amin R, et al. 2017. Editor’s highlight: In utero exposure to gadolinium and adverse neonatal outcomes in premature infants. Toxicol Sci, 156(2):520-526.
  • Bird ST. 2019. First-trimester exposure to gadolinium-based contrast agents: a utilization study of 4.6 million U.S. pregnancies. Radiology, 293(1):193–200.
  • Chartier AL, et al. 2019. The safety of maternal and fetal MRI at 3 T. American Journal of Roentgenology, 213(5): 1170–1173.
  • Kallmes DF & Watson RE. 2019. Gadolinium administration in undetected pregnancy: cause for alarm? Radiology, 293(1):201–202.
  • Mervak BM, et al. 2019. MRI in pregnancy: Indications and practical considerations. Journal of Magnetic Resonance Imaging, JMRI, 49(3):621–631.
  • Murata N, et al. 2016. Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: Preliminary results From 9 patients with normal renal function. Invest Radiol, 51(7):447-453.
  • Patenaude Y, et al. 2014. The use of magnetic resonance imaging in the obstetric patient. J Obstet Gynaecol Can, 36:349-355.
  • Ray JG, et al. 2016. Association between MRI exposure during pregnancy and fetal and childhood outcomes. JAMA, 316(9):952-961.
  • Rogosnitzky M, Branch S. 2016. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals, 29:365-376.
  • US Food and Drug Administration (FDA). 2018. Information on Gadolinium-Based Contrast Agents. Available at: https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm142882.htm
  • Webb JA, et al, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). 2005. The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol, 15:1235-1240.

Footer

           

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Asthma
  • Coronavirus (COVID-19)
  • Crohn’s Disease
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Juvenile Idiopathic Arthritis
  • Multiple Sclerosis
  • Pertussis/Tdap vaccine (“Whooping Cough” vaccine)
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists
OTIS Logo

Copyright © 2023 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^